Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects

Endocrine Reviews

Volumn 34, Issue 2, 2013, Pages 171-208

  Stanczyk, Frank Z ^a   Hapgood, Janet P ^b   Winer, Sharon ^a   Mishell, Daniel R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; CYTOCHROME P450; DEMEGESTONE; DESOGESTREL; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; PROGESTERONE; PROGESTERONE RECEPTOR; PROMEGESTONE; STEROID RECEPTOR; TESTOSTERONE; TIBOLONE; TRANSCORTIN; TRIMEGESTONE; UNINDEXED DRUG; VASCULOTROPIN;

BINDING AFFINITY; BINDING SITE; BONE DENSITY; BREAST CANCER; BREAST CARCINOMA; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHROMATIN STRUCTURE; DNA METHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; GENE EXPRESSION; HUMAN; NERVOUS SYSTEM; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 84876059228     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1008     Document Type: Review

References (314)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, et al. 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
3. Stanczyk FZ, Henzl MR 2001 Use of thename"Progestin." Contraception 64:1-2
4. North American Menopause Society 2003 Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society. Menopause 10:113-132
5. Stanczyk FZ 2003 All progestins are not created equal. Steroids 68:879-890
6. Henzl ME 1978 Natural and synthetic female sex hormones. In: Yen SCC, Jaffe RB, eds. Reproductive endocrinology: physiology, pathophysiology and clinical management. Philadelphia: WB Saunders; 421-468
7. Kuhl H 2005 Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8(Suppl 1):3-63
8. Stanczyk FZ, Roy S 1990 Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 42:67-96
9. Edgren RA, Stanczyk FZ 1999 Nomenclature of the gonane progestins. Contraception 60:313
10. Stanczyk FZ 2000 Pharmacokinetics of progesterone administered orally and parenterally. In: Sitruk-Ware R, Mishell Jr DR, eds. Progestins and antiprogestins in clinical practice. New York: Marcel-Dekker; 393-400
11. Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K 1997 In vivo conversion of norethesterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 56:379-385
12. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA 2007 Formation of ethinyl estradiol inwomenduring treatment with norethindrone acetate. J Clin Endocrinol Metab 92:2205-2207
13. Hammond GL, Lähteenmäki PL, Lähteenmäki P, Luukkainen T 1982 Distribution and percentage of non-protein bound contraceptive steroids in human serum. J Steroid Biochem 17:375-380
14. Kuhnz W, Pfeffer M, al-Yacoub G 1990 Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. J Steroid Biochem 35:313-318
15. Westphal U 1974 Steroid-protein interactions. Berlin: Springler-Verlag
16. Simon JA, Robinson DE, Andrews MC, Hildebrand 3rd JR, Rocci Jr ML, Blake RE, Hodgen G D 1993 The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril 60:26-33
17. Victor A, Johansson ED 1976 Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally. Contraception 14:319-329
18. Farinha A, Bica A, Tavares P 2000 Improved bioavailability of a micronized megestrol acetate tablet formulation in humans. Drug Dev Ind Pharm 26:567-570
19. Kuhnz W, Staks T, Jütting G 1993 Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception 48:557-575
20. Kuhl H 1990 Pharmacokinetics of oestrogens and progestogens. Maturitas 12:171-197
21. Lin WJ, Her SJ, Chen PF, Chen RR 1998 Determination of medrogestone in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 714:263-268
22. Mueck AO, Sitruk-Ware R 2011 Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76:531-539
23. Back DJ, Breckenridge AM, Crawford FE, Mciver M, Orme ML, Rowe PH, Smith E 1978 Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther 24:448-453
24. Back DJ, Bates M, Breckenridge A M,Hall JM, MacIver M, Orme ML, Park BK, Rowe PH 1981 The pharmacokinetics of levonorgestrel and ethynylestradiol in women: studies with Ovran and Ovranette. Contraception 23:229-239
25. Bergink W, Assendorp R, Kloosterboer L, van Lier W, Voortman G, Qvist I 1990 Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. Am J Obstet Gynecol 163:2132-2137
26. Back DJ, Grimmer SF, Shenoy N, Orme ML 1987 Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-ketodesogestrel. Contraception 35:619-626
27. Orme M, Back DJ, Ward S, Green S 1991 The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel. Contraception 43:305-316
28. Täuber U, Tack JW, Matthes H 1989 Single dose pharmacokinetics of gestodene in women after intravenous and oral administration. Contraception 40:461-479
29. Oettel M, Bervoas-Martin S, Elger W, Golbs S, Hobe G, Kaufmann G, Mathieu M, Moore C, Schneider B, Puri C, Ritter P, Reddersen G, Schon R, Strauch G, Zimmermann H 1995 A19-norprogestin without a 17α-ethinyl group. II. Dienogest from a pharmacokinetic point of view. Drugs Today 31:499-516
30. Blode H, Wuttke W, Loock W, Röll G, Heithecker R 2000 Al-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 5:256-264
31. Krattenmacher R 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62:29-38
32. Nillius SJ, Johansson EDB 1971 Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol 110:470-477
33. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV 1994 Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62:485-490
34. Stanczyk FZ, Paulson RJ, Roy S 2005 Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause 12:232-237
35. Leonetti HB, Wilson KJ, Anasti JN 2003 Topical progesterone cream has an antiproliferative effect on estrogenstimulated endometrium. Fertil Steril 79:221-222
36. Wren BG, McFarland K, Edwards L, O'Shea P, Sufi S, Gross B, Eden JA 2000 Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 3:155-160
37. Product insert 2007 Climara Pro. Wayne, NJ: Bayer HealthCare Pharmaceuticals
38. Harrison LI, Zurth C, Gunther C, Karara AH, Melikian A, Lipp R 2007 Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations. Drug Dev Ind Pharm 33:373-380
39. Product insert 2006 CombiPatch. East Hanover, NJ: Novartis Pharmaceuticals
40. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA 2006 International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58:782-797
41. Africander D, Verhoog N, Hapgood JP 2011 Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 76:636-652
42. Moore NL, Hickey TE, Butler LM, Tilley WD 2012 Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Mol Cell Endocrinol 357:60-70
43. Lavery DN, McEwan IJ 2005 Structure and function of steroid receptorAF1transactivation domains: induction of active conformations. Biochem J 391:449-464
44. Griekspoor A, Zwart W, Neefjes J, Michalides R 2007 Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal 5:e003
45. Tang Y, Getzenberg RH, Vietmeier BN, Stallcup MR, Eggert M, Renkawitz R, DeFranco DB 1998 The DNA-binding and ι2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal. Mol Endocrinol 12:1420-1431
46. Bourguet W, Germain P, Gronemeyer H 2000 Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 21:381-388
47. Beato M, Klug J 2000 Steroid hormone receptors: an update. Hum Reprod Update 6:225-236
48. Weatherman RV, Fletterick RJ, Scanlan TS 1999 Nuclearreceptor ligands and ligand-binding domains. Ann Rev Biochem 68:559-581
49. Tanenbaum DM, Wang Y, Williams SP, Sigler PB 1998 Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 95:5998-6003
50. Williams SP, Sigler PB 1998 Atomic structure of progesterone complexed with its receptor. Nature 393:392-396
51. Fuller PJ 1991 The steroid receptor superfamily: mechanisms of diversity. FASEB J 5:3092-3099
52. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-895
53. Loosfelt H, AtgerM,MisrahiM,Guiochon-Mantel A,Meriel C, Logeat F, Benarous R, Milgrom E 1986 Cloning and sequence analysis of rabbit progesterone-receptor complementary DNA. Proc Natl Acad Sci USA 83:9045-9049
54. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ,McKee D D, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105
55. Kastner P, Bocquel MT, Turcotte B, Garnier JM, Horwitz KB, Chambon P, Gronemeyer H 1990 Transient expression ofhumanand chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. J Biol Chem 265:12163-12167
56. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB 1994 Athird transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8:1347-1360
57. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP 1994 The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14:8356-8364
58. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP 2000 The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20:3102-3115
59. Oakley RH, Cidlowski JA 2011 Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 286:3177-3184
60. Zhou J, Cidlowski JA 2005 The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70:407-417
61. Mangal RK, Wiehle RD, Poindexter 3rd AN, Weigel NL 1997 Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Mol Biol 63:195-202
62. Soyal SM, Mukherjee A, Lee KY, Li J, Li H, DeMayo FJ, Lydon JP 2005 Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis 41: 58-66
63. Shyamala G, Schneider W, Schott D 1990 Developmental regulation of murinemammaryprogesterone receptor gene expression. Endocrinology 126:2882-2889
64. Mulac-Jericevic B, Conneely OM 2004 Reproductive tissue selective actions of progesterone receptors. Reproduction 128:139-146
65. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW 2002 Reproductive functions of progesterone receptors. Recent Prog Horm Res 57:339-355
66. Khan JA, Amazit L, Bellance C, Guiochon-Mantel A, Lombe' s M, Loosfelt H 2011 p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol 25:1710-1724
67. Mesiano S, Wang Y, Norwitz ER 2011 Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci 18:6-19
68. Deroo BJ, Korach KS 2006 Estrogen receptors and human disease. J Clin Invest 116:561-570
69. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat A M, Chaouat M, Forgez P, Gompel A 2012 Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 131:49-63
70. Krozowski ZS, Funder JW 1983 Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 80:6056-6060
71. de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W 2000 Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 57:1329-1336
72. Funder JW 2004 Aldosterone, mineralocorticoid receptors and vascular inflammation.MolCell Endocrinol 217:263-269
73. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP 2005 Synthetic progestogens used inHRThave different glucocorticoid agonist properties. Mol Cell Endocrinol 242:23-32
74. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M 1999 The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 13:316-326
75. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL 1990 Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41:399-410
76. Juchem M, Pollow K, Elger W, Hoffmann G, Möbus V 1993 Receptor binding of norgestimate: a new orally active synthetic progestational compound. Contraception 47: 283-294
77. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM 1999 Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab 84:4055-4061
78. Bergink EW, van Meel F, Turpijn EW, van der Vies J 1983 Binding of progestagens to receptor proteins in MCF-7 cells. J Steroid Biochem 19:1563-1570
79. 15, and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals. J Steroid Biochem Mol Biol 74:83-92
80. Chávez BA, Vilchis F, Pérez AE, García GA, Grillasca I, Pérez-Palacios G 1985 Stereospecificity of the intracellular binding of norethisterone and its A-ring reduced metabolites. J Steroid Biochem 22:121-126
81. Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J 1980 Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 40:2557-2561
82. Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ 2000 Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol 74:213-222
83. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM 1999 Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 13:440-454
84. Pérez-Palacios G, Chávez B, Escobar N, Vilchis F, Larrea F, Lince M, Pérez AE 1981 Mechanism of action of contraceptive synthetic progestogens. J Steroid Biochem 15: 125-130
85. Hackenberg R, Hawighorst T, Filmer A, Nia AH, Schulz KD 1993 Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat 25:217-224
86. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD 1999 Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 154:11-20
87. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH 2003 Classification and pharmacology of progestogens. Maturitas 46(Suppl 1):S7-S16
88. Sitruk-Ware R 2004 Pharmacological profile of progestogens. Maturitas 47:277-283
89. Fotherby K 1990 Interactions with oral contraceptives. Am J Obstet Gynecol 163:2153-2159
90. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH 1996 The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54:243-251
91. Wambach G, Higgins JR, Kem DC, Kaufmann W 1979 Interaction of synthetic progestagens with renal mineralocorticoid receptors. Acta Endocrinol (Copenh) 92:560-567
92. Rafestin-Oblin ME, Lombes M, Couette B, Baulieu EE 1992 Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor. J Steroid Biochem Mol Biol 41:815-821
93. Quinkler M, Diederich S 2002 Difference of in vivo and in vitro antimineralocorticoid potency of progesterone. Endocr Res 28:465-470
94. Genazzani A, Gambacciani M, Simoncini T, Anniverno R, Becorpi AM, Biglia N, Brandi ML, Guaschino S, Lello S, Massobrio M, Melis GB, Mencacci C, Modena MG, Nappi C, Nappi RE, Pecorelli S, Petraglia F, Rosano GM, Serra GB, Sismondi P, Taddei S, Tonelli F 2007 Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. Gynecol Endocrinol 23:436-444
95. Winneker RC, Bitran D, Zhang Z 2003 The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 68:915-920
96. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A 2003 Conception and pharmacodynamic profile of drospirenone. Steroids 68:891-905
97. Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, Kato S, Mizuguchi K 2008 Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 73:222-231
98. Koubovec D, Vanden Berghe W, Vermeulen L, Haegeman G, Hapgood JP 2004 Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 221:75-85
99. Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons Jr SS, Louw A, Hapgood JP 2009 Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction.MolCell Endocrinol 299:219-231
100. Kontula K, Paavonen T, Luukkainen T, Andersson LC 1983 Binding of progestogens to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 32:1511-1518
101. Fuhrmann U, Slater EP, Fritzemeier KH 1995 Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception 51: 45-52
102. McPhail MK 1934 The assay of progestin. J Physiol 83: 145-156
103. Edgren RA 1994 Issues in animal pharmacology. In: Goldzieher JW, Fotherby K, eds. Pharmacology of the contraceptive steroids. New York: Raven Press; 81-97
104. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR 2005 Quantitative analysis of gene regulation by seven clinically relevant progestogens suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 97:328-341
105. Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB 2005 The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res 7:R1036-R1050
106. Hyder SM, Murthy L, Stancel GM 1998 Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392-395
107. Mueller MD, Vigne JL, Pritts EA, Chao V, Dreher E, Taylor RN 2003 Progestogens activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells. Fertil Steril 79:386-392
108. Fu XD, Giretti MS, Goglia L, Flamini MI, Sanchez AM, Baldacci C, Garibaldi S, Sitruk-Ware R, Genazzani AR, Simoncini T 2008 Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer 8:166
109. Lello S 2010 Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 70:541-559
110. van Diepen HA, Lam TW, Kuil CW 2011 Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey. Contraception 84:199-204
111. Greenblatt RB, Jungck EC, Barfield WE 1958 A new test of efficacy of progestational compounds. AnnNYAcad Sci 71:717-721
112. Swyer GI, Little V 1968 Clinical assessment of relative potency of progestogens. J Reprod Fertil Suppl 5:63-68
113. Dorflinger LJ 1985 Relative potency of progestins used in oral contraceptives. Contraception 31:557-570
114. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB 1981 Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305:1599-1605
115. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T, Lane G, Siddle NC, King RJB 1982 Effects of various types and dosages of progestins on the postmenopausal endometrium. J Reprod Med 27:539-548
116. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI 1983 Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J (Clin Res Ed) 287:1241-1245
117. Whitehead MI, Lane G, Siddle NC, Townsend PT, King RJ 1983 Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women. Semin Reprod Endocrinol 1:41
118. Whitehead MI, Siddle NC, Townsend PT, Lane G, King RJ 1983 The use of progestins and progesterone in the treatment of climacteric and postmenopausal symptoms. In: CW Bardin, E Milgrom, P Mauvais Jarvis, eds. Progesterone and progestins. New York: Raven Press; 277
119. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI 1986 Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obstet Gynaecol 93:55-62
120. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI 1986 Is Provera the ideal progestin for addition to postmenopausal estrogen therapy? Fertil Steril 45:345-352
121. King RJ, Whitehead MI 1986 Assessment of the potency of orally administered progestins in women. Fertil Steril 46: 1062-1066
122. Vicent GP, Nacht AS, Zaurín R, Ballaré C, Clausell J, Beato M 2010 Role of kinases and chromatin remodeling in progesterone signaling to chromatin. Mol Endocrinol 24:2088-2098
123. Biddie SC, John S, Hager GL 2010 Genome-wide mechanisms of nuclear receptor action. Trends Endocrinol Metab 21:3-9
124. Leslie KK, Stein MP, Kumar NS, Dai D, Stephens J, Wandinger-Ness A, Glueck DH 2005 Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 96:32-41
125. Lim CS, Baumann CT, Htun H, Xian W, Irie M, Smith CL, Hager GL 1999 Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras. Mol Endocrinol 13: 366-375
126. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
127. Hammes SR, Levin ER 2007 Extranuclear steroid receptors: nature and actions. Endocr Rev 28:726-741
128. Perissi V, Rosenfeld MG 2005 Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542-554
129. Beato M 1989 Gene regulation by steroid hormones. Cell 56:335-344
130. Ballaré C, Uhrig M, Bechtold T, Sancho E, Di Domenico M,Migliaccio A, Auricchio F, Beato M 2003 Twodomains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23: 1994-2008
131. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, Chambon P 2011 Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145:224-241
132. Kassel O, Herrlich P 2007 Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects. Mol Cell Endocrinol 275:13-29
133. De Bosscher K, Haegeman G 2009 Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol 23:281-291
134. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
135. De Bosscher K, VandenBerghe W, Haegeman G 2003 The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24:488-522
136. Revollo JR, Cidlowski JA 2009 Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 1179:167-178
137. Kobayashi S, Stice JP, Kazmin D, Wittmann BM, Kimbrel EA, Edwards DP, Chang CY, McDonnell DP 2010 Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. Mol Endocrinol 24:2292-2302
138. McKay LI, Cidlowski JA 1999 Molecular control of immune/ inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev 20:435-459
139. Kalkhoven E, Wissink S, van der Saag PT, van der Burg B 1996 Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J Biol Chem 271: 6217-6224
140. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Jänne OA 1996 Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 271: 24151-24156
141. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC 1995 Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886-2895
142. Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S 1997 A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J Biol Chem 272:21467-21472
143. Faivre EJ, Daniel AR, Hillard CJ, Lange CA 2008 Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22:823-837
144. Faivre EJ, Lange CA 2007 Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 27:466-480
145. Goldhar AS, Duan R, Ginsburg E, Vonderhaar BK 2011 Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C/EBP. Mol Cell Endocrinol 335:148-157
146. Nettles KW, Greene GL 2005 Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol 67:309-333
147. McKenna NJ, Lanz RB, O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344
148. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200
149. Reddy TE, Pauli F, Sprouse RO, Neff NF, Newberry KM, Garabedian MJ, Myers RM 2009 Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res 19:2163-2171
150. Hakim O, Sung MH, Hager GL 2010 3D shortcuts to gene regulation. Curr Opin Cell Biol 22:305-313
151. Xi H, Shulha HP, Lin JM, Vales TR, Fu Y, Bodine DM, McKay RD, Chenoweth JG, Tesar PJ, Furey TS, Ren B, Weng Z, Crawford GE 2007 Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome. PLoS Genet 3:e136
152. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, Ching KA, Antosiewicz-Bourget JE, Liu H, Zhang X, Green RD, Lobanenkov VV, Stewart R, Thomson JA, Crawford G E, Kellis M, Ren B 2009Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459:108-112
153. Santos GM, Fairall L, Schwabe JW 2011 Negative regulation by nuclear receptors: a plethora of mechanisms. Trends Endocrinol Metab 22:87-93
154. Hu Q, Kwon YS, Nunez E, Cardamone MD, Hutt KR, Ohgi KA, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG, Fu XD 2008 Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci USA 105:19199-19204
155. Beral V; Million Women Study Collaborators 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet [Erratum (2003) 362:1160] 362: 419-427
156. Kaunitz AM 2006 Hormone therapy and breast cancer risk: trumping fear with facts. Menopause 13:160-163
157. Colditz GA 2005 Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11:909s-917s
158. Rosano GM, Fini M 2001 Comparative cardiovascular effects of different progestogens in menopause. Int J Fertil Womens Med 46:248-256
159. Sitruk-Ware R 2000 Progestins and cardiovascular risk markers. Steroids 65:651-658
160. Brunelli R, Frasca D, Perrone G, Pioli C, Fattorossi A, Zichella L, Doria G 1996 Hormone replacement therapy affects various immune cell subsets and natural cytotoxicity. Gynecol Obstet Invest 41:128-131
161. Malarkey WB, Burleson M, Cacioppo JT, Poehlmann K, Glaser R, Kiecolt-Glaser JK 1997 Differential effects of estrogen and medroxyprogesterone on basal and stressinduced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women. Endocrine 7:227-233
162. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T 2002 Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 105:1436-1439
163. Stopiń ska-Głuszak U, Waligóra J, Grzela T, Głuszak M, Jóźwiak J, Radomski D, Roszkowski PI, Malejczyk J 2006 Effect of estrogen/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women. J Reprod Immunol 69:65-75
164. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N 1995 Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 6:99-107
165. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones 3rd BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J 2003 Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2651-2662
166. Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P 2004 Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 81:617-623
167. Odmark IS, Bäckström T, Jonsson B, Bixo M 2004 Longterm effects of two different continuous combined regimens of hormone replacement therapy on well-being. Gynecol Endocrinol 18:305-317
168. Oelkers W 2004 Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 217:255-261
169. Liu L,ZhaoL, She H,ChenS,WangJM,WongC, McClure K, Sitruk-Ware R, Brinton RD 2010 Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Endocrinology 151:5782-5794
170. Zhao D, Lebovic DI, Taylor R N 2002 Long-term progestin treatment inhibits RANTES (regulated on activation, normal T cell expressed and secreted) gene expression in human endometrial stromal cells. J Clin Endocrinol Metab 87:2514-2519
171. Ramhorst R, Patel R, Corigliano A, Etchepareborda JJ, Fainboim L, Schust D 2006 Induction of maternal tolerance to fetalalloantigens by RANTES production. Am J Reprod Immunol 56:302-311
172. Tatsumi H, Kitawaki J, Tanaka K, Hosoda T, Honjo H 2002 Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestogens. Maturitas 42:287-294
173. Yasa M, Turkseven S 2005 Vasoprotective effects of nitric oxide in atherosclerosis. FABAD J Pharm Sci 30:41-53
174. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR 2004 Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145:5745-5756
175. Simoncini T, Mannella P, Pluchino N, Genazzani A 2007 Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels. Gynecol Endocrinol 23(Suppl 1):9-16
176. Irwin RW, Yao J, Ahmed SS, Hamilton RT, Cadenas E, Brinton RD 2011 Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Endocrinology 152:556-567
177. Schneider HP 2003 Androgens and antiandrogens. Ann NY Acad Sci 997:292-306
178. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E 1995 Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 761:311-335
179. Zhang Z, Lundeen SG, Zhu Y, Carver JM, Winneker RC 2000 In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 65:637-643
180. García-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Pérez-Palacios G, Larrea F 2004 Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestogens. J Steroid Biochem Mol Biol 91:21-27
181. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP 2011 Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 84:423-435
182. Birrell SN, Butler LM, Harris JM, Buchanan G, TilleyWD 2007 Disruption of androgen receptor signaling by synthetic progestogens may increase risk of developing breast cancer. FASEB J 21:2285-2293
183. Hadley KE, Louw A, Hapgood JP 2011 Differential nuclear localisation and promoter occupancy play a role in glucocorticoid receptor ligand-specific transcriptional responses. Steroids 76:1176-1184
184. Ishida Y, Ishida Y, Heersche JN 2002 Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos Int 13: 601-605
185. Ishida Y, Mine T, Taguchi T 2008 Effect of progestogens with different glucocorticoid activity on bone metabolism. Clin Endocrinol (Oxf) 68:423-428
186. Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H 2003 Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. Thyroid 13:249-258
187. Zhao Q, Pang J, Favata MF, Trzaskos JM 2003 Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression. Int Immunopharmacol 3:1803-1817
188. Thomas CP, Liu KZ, Vats HS 2006 Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate _-ENaC and sgk1 expression in renal collecting duct epithelia. Am J Physiol Renal Physiol 290:F306-F312
189. Ouatas T, Halverson D, Steeg PS 2003 Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 9:3763-3772
190. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB 2007 Progestogens overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 21:265-273
191. Spangelo BL, Gorospe WC 1995 Role of the cytokines in the neuroendocrine-immune system axis. Front Neuroendocrinol 16:1-22
192. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR 2002 Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16:61-71
193. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB 2001 Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 104:2826-2831
194. Moutsatsou P, Papavassiliou AG 2008 The glucocorticoid receptor signalling in breast cancer. J Cell Mol Med 12: 145-163
195. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, Gompel A 2012 Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 131:49-63
196. Wan Y, Nordeen SK 2002 Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol 16:1204-1214
197. Oelkers WK 1996 Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 61:166-171
198. Rylance PB, Brincat M, Lafferty K, De Trafford JC, Brincat S, Parsons V, Studd JW 1985 Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed) 290:13-14
199. Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V 2002 Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur J Endocrinol 146: 789-799
200. Oelkers W 2005 Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 8(Suppl 3):19-27
201. Arias-Loza PA, Muehlfelder M, Elmore SA, Maronpot R, HuK, Blode H, Hegele-Hartung C, FritzemeierKH,Ertl G, Pelzer T 2009 Differential effects of 17_-estradiol and of synthetic progestogens on aldosterone-salt-induced kidney disease. Toxicol Pathol 37:969-982
202. Seeger H, Wallwiener D, Mueck AO 2009 Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 12:80-87
203. Di Carlo F, Gallo E, Conti G, Racca S 1983 Changes in the binding of oestradiol to uterine oestrogen receptors in-duced by some progesterone and 19-nor-testosterone derivatives. J Endocrinol 98:385-389
204. Markiewicz L, Gurpide E 1994 Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells. J Steroid Biochem Mol Biol 48:89-94
205. Mendoza-Rodríguez CA, Camacho-Arroyo I, García GA, Cerbón MA 1999 Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites. Contraception 59:339-343
206. Larrea F, García-Becerra R, Lemus AE, García GA, Pérez-Palacios G, Jackson KJ, Coleman KM, Dace R, Smith CL, Cooney AJ 2001 A-ring reduced metabolites of 19-nor synthetic progestogens as subtype selective agonists for ERα. Endocrinology 142:3791-3799
207. Stellato C 2004 Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 1:255-263
208. Wierman ME 2007 Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 31:26-33
209. Grossmann C, Gekle M 2009 New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 308:53-62
210. ZhuY, Hanna RN, Schaaf MJ, Spaink HP, Thomas P 2008 Candidates for membrane progestin receptors: past approaches and future challenges. Comp Biochem Physiol C Toxicol Pharmacol 148:381-389
211. Nilsen J, Brinton RD 2003 Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 100:10506-10511
212. Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP 2008 The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids 73:922-928
213. Hagan CR, Daniel AR, Dressing GE, Lange CA 2012 Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol 357:43-49
214. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV 2005 Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 25:4826-4840
215. Béguelin W, Díaz Flaqué MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV 2010 Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol 30:5456-5472
216. Thomas P 2008 Characteristics of membrane progestin receptor α (mPRα) and progesterone membrane receptor component 1(PGMRC1)and their roles in mediating rapid progestin actions. Front Neuroendocrinol 29:292-312
217. Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J, Zhu Y, Tubbs C 2007 Steroid and G protein binding characteristics of the sea trout and human progestin membrane receptor α subtypes and their evolutionary origins. Endocrinology 148:705-718
218. Dosiou C, Hamilton AE, Pang Y, Overgaard MT, Tulac S, Dong J, Thomas P, Giudice LC 2008 Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J Endocrinol 196:67-77
219. Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, Takahashi T, Igarashi H, Mori-Abe A, Du B, Tsutsumi S, Kurachi H 2005 Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/ nuclear factor-_B cascade in human breast cancer cells. Endocrinology 146:4917-4925
220. Limbourg FP, Huang Z, Plumier JC, Simoncini T, Fujioka M, Tuckermann J, Schütz G, Moskowitz MA, Liao JK 2002 Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 110:1729-1738
221. Raz L, KhanMM,Mahesh VB, Vadlamudi RK, BrannDW 2008 Rapid estrogen signaling in the brain. Neurosignals 16:140-153
222. Walker WH 2003 Nongenomic actions of androgen in Sertoli cells. Curr Top Dev Biol 56:25-53
223. Rarick L 2007 United States regulatory considerations for intrauterine progestins for hormone replacement therapy. Contraception 75:S140-S143
224. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, Mc-Naney-Flint H, Downs R, Mortola J, Watts N, Yang HM, Banav N, Brennan JJ, Nolan JC 1997 Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 157:2609-2615
225. Ettinger B, Ensrud KE, Wallace R, Johnson KC,Cummings SR, Yankov V, Vittinghoff E, Grady D 2004 Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104:443-451
226. Beral V, Bull D, Reeves G Million Women Study Collaborators 2005 Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543-1551
227. The Writing Group for the PEPI Trial 1996 Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 275:370-375
228. Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E, Bakken K, Gavrilyuk O, Overvad K, Tjønneland A, Olsen A, Fournier A, Fabre A, Clavel-Chapelon F, Chabbert-Buffet N, Sacerdote C, Krogh V, Bendinelli B, Tumino R, Panico S, Bergmann M, Schuetze M, van Duijnhoven FJ, Bueno-de-Mesquita HB, Onland-Moret NC, et al. 2010 Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 172:1394-1403
229. Cicinelli E, de Ziegler D, Galantino P, Pinto V, Barba B, Morgese S, Schonauer S 2002 Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 187:556-560
230. Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G 2005 Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 83:1859-1863
231. Hampton NR, ReesMC,Lowe DG, Rauramo I, Barlow D, Guillebaud J 2005 Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 20:2653-2660
232. Suvanto-Luukkonen E, Kauppila A 1999 The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 72:161-163
233. Varila E, Wahlström T, Rauramo I 2001 A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 76:969-973
234. Seeger H, Mueck AO 2008 Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? J Steroid Biochem Mol Biol 109:11-15
235. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators 2006 Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647-1657
236. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, RavdinPM,Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators 2010 Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684-1692
237. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253
238. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E 1999 Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130:262-269
239. Lundström E, Bygdeson M, Svane G, Azavedo E, von Schoultz B 2007 Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 10:249-256
240. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, Weber AL, Doody DR, Wingo PA, McDonald JA, Malone KE, Folger SG, Spirtas R 2002 Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 100:1148-1158
241. Olsson HL, Ingvar C, Bladström A 2003 Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97:1387-1392
242. Ross RK, Paganini-Hill A, Wan PC, Pike MC 2000 Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328-332
243. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA [Erratum (2000) 284:2597] 283:485-491
244. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR 2003 Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254-3263
245. Chen CL, Weiss NS, Newcomb P, Barlow W, White E 2002 Hormone replacement therapy in relation to breast cancer. JAMA 287:734-741
246. Jick SS, Hagberg KW, Kaye JA, Jick H 2009 Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol 113:74-80
247. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA 2003 Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21: 4314-4321
248. Collins JA, Blake JM, Crosignani PG 2005 Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update [Erratum (2006) 12:331] 11:545-560
249. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C 2009 Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer [Erratum (2009) 115:1587] 115:936-945
250. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D, Martin L, Ockene J, Rohan T, Schenken R, Wactawski-Wende J 2012 Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13:476-486
251. Chlebowski RT, Anderson GL 2012 Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 104:517-527
252. Brinton LA, Lacey Jr JV, Trimble EL 2005 Hormones and endometrial cancer-new data from the Million Women Study. Lancet 365:1517-1518
253. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F 2005 Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448-454
254. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA 2007 The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674
255. Grady D, Herrington D, Bittner V, Blumenthal R, DavidsonM, HlatkyM,Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group 2002 Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA [Erratum (2002) 288:1064] 288:49-57
256. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M;Women's Health Initiative Investigators 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
257. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML 2007 Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-1477
258. RosanoGM,Vitale C, Fini M 2009 Cardiovascular aspects of menopausal hormone replacement therapy. Climacteric 12(Suppl 1):41-46
259. Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC 2008 Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med 5:387-395
260. Writing Group for the PEPI Trial 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA 273:199-208
261. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P 2000 Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 36:2154-2159
262. Mishra RG, Hermsmeyer RK, Miyagawa K, Sarrel P, Uchida B, Stanczyk FZ, Burry KA, Illingworth DR, Nordt FJ 2005 Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys. J Clin Endocrinol Metab 90:3706-3714
263. 2+ release mechanism of primate drug-induced coronary vasospasm. Am J Physiol 272:H2645-H2654
264. Minshall RD, Stanczyk FZ, Miyagawa K, Uchida B, Axthelm M, Novy M, Hermsmeyer K 1998 Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab 83:649-659
265. Hermsmeyer RK, Mishra RG, Pavcnik D, Uchida B, Axthelm MK, Stanczyk FZ, Burry KA, Illingworth DR, Kaski JC, Nordt FJ 2004 Prevention of coronary hyperreactivity in pre-atherogenic menopausal rhesus monkeys by transdermal progesterone. Arteriosclerosis Thromb Vasc Biol 24:955-961
266. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT 1996 The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 45:1254-1262
267. Al-Azzawi F, Thompson J, Stevenson J 2006 Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence. Maturitas 54:154-163
268. Godsland IF 2001 Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 75:898-915
269. Shulman LP 2002 Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. Am J Cardiol 89:47E-54E; discussion 54E-55E
270. Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M 2008 Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone. Thromb Haemost 100:253-260
271. Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY 2010 Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 17:1122-1127
272. Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY 2010 Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 30:340-345
273. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C 2006 Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 53:252-259
274. Koh KK, Jin DK, Yang SH, Lee SK,HwangHY, KangMH, Kim W, Kim DS, Choi IS, Shin EK 2001 Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 103:1961-1966
275. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK 1997 Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 82:388-394
276. White WB, Hanes V, Chauhan V, Pitt B 2006 Effects of a newhormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension. Hypertension 48:246-253
277. White WB, Hanes V, Mallareddy M, Chauhan V 2008 Effects of the hormone therapy, drospirenone and 17-β estradiol, on early morning blood pressure in postmenopausal women with hypertension. J Am Soc Hypertens 2:20-27
278. Simoncini T, Genazzani AR 2010 A review of the cardiovascular and breast actions of drospirenone in preclinical studies. Climacteric 13:22-33
279. Schneider C, Jick SS, Meier CR 2009 Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 12:445-453
280. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group 2007 Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:840-845
281. Gomes MP, Deitcher SR 2004 Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164:1965-1976
282. Sehovic N, Smith KP 2010 Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann Pharmacother 44:898-903
283. Parkin L, Sharples K, Hernandez RK, Jick SS 2011 Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested casecontrol study based on UK General Practice Research Database. BMJ 342:d2139
284. Jick SS, Hernandez RK 2011 Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared withwomenusing oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 342:d2151
285. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E 2011 2011 Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 343:d6423
286. Tsutsui K 2008 Progesterone biosynthesis and action in the developing neuron. Endocrinology 149:2757-2761
287. Singh M 2007 Progestins and neuroprotection: are all progestins created equal? Minerva Endocrinol 32:95-102
288. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM,Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG 2007 ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 49:391-402, 402.e1-e2
289. Xiao G, Wei J, Yan W, Wang W, Lu Z 2008 Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 12:R61
290. Hu Z, Li Y, Fang M, Wai MS, Yew DT 2009 Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration. Curr Med Chem 16:1418-1425
291. Stein DG, Wright DW 2010 Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs 19:847-857
292. Schumacher M, Sitruk-Ware R, De Nicola AF 2008 Progesterone and progestins: neuroprotection and myelin repair. Curr Opin Pharmacol [Erratum (2009) 9:227] 8:740-746
293. Ciriza I, Carrero P, Frye CA, Garcia-Segura LM 2006 Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. J Neurobiol 66:916-928
294. Singh M 2006 Progesterone-induced neuroprotection. Endocrine 29:271-274
295. Nilsen J, Brinton RD 2002 Impact of progestins on estrogeninduced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143:205-212
296. Nilsen J, Brinton RD 2003 Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 100:10506-10511
297. Nilsen J, Morales A, Brinton RD 2006 Medroxyprogesterone acetate exacerbates glutamate excitotoxicity. Gynecol Endocrinol 22:355-361
298. Wright DW, Hoffman SW, Virmani S, Stein DG 2008 Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats. Brain Inj 22:107-113
299. Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C 2009 Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 72:135-142
300. Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, Akwa Y, Rajkowski K, Baulieu EE 2007 Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 28:387-439
301. Nelson HD 2002 Hormone replacement therapy and osteoporosis. Systematic Evidence Reviews No. 12. Rockville, MD: Agency for Healthcare Research and Quality. http:// www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book_es12
302. Dören M, Nilsson JA, Johnell O 2003 Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis.HumReprod 18:1737-1746
303. Abdalla HI, Hart DM, Lindsay R, Leggate I,Hooke A 1985 Prevention of bone mineral loss in postmenopausalwomen by norethisterone. Obstet Gynecol 66:789-792
304. Gallagher JC, Kable WT, Goldgar D 1991 Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 90:171-178
305. Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC 1994 Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 96:521-530
306. Prior JC, Tremollieres F, Forsmo S, Seifert-Klauss V 2006 Unsuccessful attempt to demonstrate progesterone's bone formation actions. Am J Obstet Gynecol 194:1502-1503; author reply 1503-1504
307. Hammond GL 2002 Access of reproductive steroids to target tissues. Obstet Gynecol Clin NorthAm29:411-423
308. Sitruk-Ware R 2007 Routes of delivery for progesterone and progestogens. Maturitas 57:77-80
309. Sitruk-Ware R 2005 Pharmacology of different progestogens: the special case of drospirenone. Climacteric 8(Suppl 3):4-12
310. Sitruk-Ware R 2006 Contraception: an international perspective. Contraception 73:215-222
311. Charles NJ, Thomas P, Lange CA 2010 Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer 1:167-176
312. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
313. Kurman RJ, Kaminski PF, Norris HJ 1985 The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56:403-412
314. Africander D 2010 Comparative study of the molecular mechanism of action of the synthetic progestins, MPA and norethisterone acetate. PhD thesis, University of Stellenbosch, South Africa